Bengaluru: Indian conglomerate Piramal Enterprises Ltd (PEL) said on Thursday it was demerging its pharmaceutical business and listing it as a separate entity as part of a move to simplify its corporate structure.
Piramal’s pharma business will now be demerged and consolidated under its unit Piramal Pharma. Shareholders of Piramal will get four shares of Piramal Pharma for every share they hold in the conglomerate.
Piramal will also merge its shadow lending unit PHL Fininvest with itself to create a large non-banking financial company, with a focus on retail and wholesale financing and a consolidated loan book of Rs 65,000 crore ($8.69 billion), the company said in an exchange filing.
The moves will enable the entities to independently pursue their growth strategies with sharper focus and identity, said Ajay Piramal, chairman of the Piramal Group.
The demerger is subject to approvals from shareholders, creditors and regulators, Piramal said.
Shares of Piramal Enterprises closed 1.6% higher on Thursday.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)